Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 29

Cited In for PubMed (Select 15547185)


Regulation of the DNA damage response by ubiquitin conjugation.

Brinkmann K, Schell M, Hoppe T, Kashkar H.

Front Genet. 2015 Mar 10;6:98. doi: 10.3389/fgene.2015.00098. eCollection 2015. Review.


LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers.

Yu H, Yue X, Zhao Y, Li X, Wu L, Zhang C, Liu Z, Lin K, Xu-Monette ZY, Young KH, Liu J, Shen Z, Feng Z, Hu W.

Nat Commun. 2014 Oct 17;5:5218. doi: 10.1038/ncomms6218.


Limiting the power of p53 through the ubiquitin proteasome pathway.

Pant V, Lozano G.

Genes Dev. 2014 Aug 15;28(16):1739-51. doi: 10.1101/gad.247452.114. Review.


Does the measles virus contribute to carcinogenesis? - a review.

Benharroch D, Gopas J, Ariad S.

J Cancer. 2014 Jan 5;5(2):98-102. doi: 10.7150/jca.7430. eCollection 2014. Review.


Residues 240-250 in the C-terminus of the Pirh2 protein complement the function of the RING domain in self-ubiquitination of the Pirh2 protein.

Abou Zeinab R, Wu H, Sergi C, Leng RP.

PLoS One. 2013 Dec 18;8(12):e82803. doi: 10.1371/journal.pone.0082803. eCollection 2013.


The homeodomain transcription factor Hoxa2 interacts with and promotes the proteasomal degradation of the E3 ubiquitin protein ligase RCHY1.

Bergiers I, Bridoux L, Nguyen N, Twizere JC, Rezsöhazy R.

PLoS One. 2013 Nov 7;8(11):e80387. doi: 10.1371/journal.pone.0080387. eCollection 2013.


Pirh2: an E3 ligase with central roles in the regulation of cell cycle, DNA damage response, and differentiation.

Halaby MJ, Hakem R, Hakem A.

Cell Cycle. 2013 Sep 1;12(17):2733-7. doi: 10.4161/cc.25785. Epub 2013 Aug 5. Review.


Role of E3 ubiquitin ligases in lung cancer.

Snoek BC, de Wilt LH, Jansen G, Peters GJ.

World J Clin Oncol. 2013 Aug 10;4(3):58-69. doi: 10.5306/wjco.v4.i3.58.


WWP1 E3 ligase targets LATS1 for ubiquitin-mediated degradation in breast cancer cells.

Yeung B, Ho KC, Yang X.

PLoS One. 2013;8(4):e61027. doi: 10.1371/journal.pone.0061027. Epub 2013 Apr 3.


Mouse models of Mdm2 and Mdm4 and their clinical implications.

Xiong S.

Chin J Cancer. 2013 Jul;32(7):371-5. doi: 10.5732/cjc.012.10286. Epub 2013 Jan 18. Review.


Pirh2 E3 ubiquitin ligase modulates keratinocyte differentiation through p63.

Jung YS, Qian Y, Yan W, Chen X.

J Invest Dermatol. 2013 May;133(5):1178-87. doi: 10.1038/jid.2012.466. Epub 2012 Dec 13.


It Takes 15 to Tango: Making Sense of the Many Ubiquitin Ligases of p53.

Love IM, Grossman SR.

Genes Cancer. 2012 Mar;3(3-4):249-63. doi: 10.1177/1947601912455198.


Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.

Jung YS, Qian Y, Chen X.

FEBS Lett. 2012 May 21;586(10):1397-402. doi: 10.1016/j.febslet.2012.03.052. Epub 2012 Apr 3. Review.


Role of Pirh2 in mediating the regulation of p53 and c-Myc.

Hakem A, Bohgaki M, Lemmers B, Tai E, Salmena L, Matysiak-Zablocki E, Jung YS, Karaskova J, Kaustov L, Duan S, Madore J, Boutros P, Sheng Y, Chesi M, Bergsagel PL, Perez-Ordonez B, Mes-Masson AM, Penn L, Squire J, Chen X, Jurisica I, Arrowsmith C, Sanchez O, Benchimol S, Hakem R.

PLoS Genet. 2011 Nov;7(11):e1002360. doi: 10.1371/journal.pgen.1002360. Epub 2011 Nov 17.


RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.

Lipkowitz S, Weissman AM.

Nat Rev Cancer. 2011 Aug 24;11(9):629-43. doi: 10.1038/nrc3120. Review.


The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation.

Jung YS, Qian Y, Chen X.

J Biol Chem. 2011 Oct 14;286(41):35388-95. doi: 10.1074/jbc.M111.261537. Epub 2011 Aug 18.


Pirh2 E3 ubiquitin ligase monoubiquitinates DNA polymerase eta to suppress translesion DNA synthesis.

Jung YS, Hakem A, Hakem R, Chen X.

Mol Cell Biol. 2011 Oct;31(19):3997-4006. doi: 10.1128/MCB.05808-11. Epub 2011 Jul 26.


Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.

Shloush J, Vlassov JE, Engson I, Duan S, Saridakis V, Dhe-Paganon S, Raught B, Sheng Y, Arrowsmith CH.

J Biol Chem. 2011 Feb 11;286(6):4796-808. doi: 10.1074/jbc.M110.157669. Epub 2010 Nov 17.


p53 post-translational modification: deregulated in tumorigenesis.

Dai C, Gu W.

Trends Mol Med. 2010 Nov;16(11):528-36. doi: 10.1016/j.molmed.2010.09.002. Review.


A newly identified Pirh2 substrate SCYL1-BP1 can bind to MDM2 and accelerate MDM2 self-ubiquitination.

Yan J, Zhang D, Di Y, Shi H, Rao H, Huo K.

FEBS Lett. 2010 Aug 4;584(15):3275-8. doi: 10.1016/j.febslet.2010.06.027. Epub 2010 Jun 23.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk